Lasmiditan for acute migraine treatment. (November 2013)

• Record Type: Journal Article
• Authors: Neeb, Lars; Reuter, Uwe
• Is Part Of: Future neurology. Volume 8:Number 6(2013)
• Page Start: 631
• Page End: 638
• Publication Date: 2013-11
• Subjects: 5-HT1F receptor agonist -- COL-144 -- lasmiditan -- migraine; Neurology -- Research -- Periodicals; 611.8005
• DOI: 10.2217/fnl.13.45
• Languages: English
• ISSNs: 1479-6708

Abstract

Lasmiditan is a new neurally acting antimigraine drug that acts as a highly selective serotonin1F receptor agonist. Its chemical structure is distinctly different from that of triptans. Its dose-dependent clinical efficacy was proven in two clinical Phase II trials using intravenous and oral formulations. Oral lasmiditan showed significant headache relief after 2 h at doses of 50, 100, 200 and 400 mg. Adverse events of lasmiditan were dose-dependent and mainly associated with the CNS. They predominantly included dizziness, paresthesia and fatigue, and were mostly mild-to-moderate in intensity. Preclinical studies showed that, unlike triptans, lasmiditan lacks any vasoconstrictive activity, which makes it a promising drug for patients with contraindications to triptans owing to cardio- or cerebro-vascular diseases, or an elevated vascular risk profile.